<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutation of the ARID1A gene and loss of the corresponding protein BAF250a has recently been described as a frequent event in clear cell and endometrioid <z:mp ids='MP_0002038'>carcinomas</z:mp> of the ovary </plain></SENT>
<SENT sid="1" pm="."><plain>To determine whether BAF250a loss is common in other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, immunohistochemistry (IHC) for BAF250a was performed on tissue microarrays (<z:chebi fb="39" ids="18139,53050">TMAs</z:chebi>) in more than 3000 cancers, including <z:mp ids='MP_0002038'>carcinomas</z:mp> of breast, lung, thyroid, endometrium, kidney, stomach, oral cavity, cervix, pancreas, colon and rectum, as well as endometrial stromal <z:hpo ids='HP_0100242'>sarcomas</z:hpo>, <z:e sem="disease" ids="C0238198" disease_type="Neoplastic Process" abbrv="GIST|GANT">gastrointestinal stromal tumours</z:e>, <z:e sem="disease" ids="C0206724" disease_type="Neoplastic Process" abbrv="">sex cord-stromal tumours</z:e> and four major types of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (diffuse large B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, primary mediastinal B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>) </plain></SENT>
<SENT sid="2" pm="."><plain>We found that BAF250a loss is frequent in <z:hpo ids='HP_0012114'>endometrial carcinomas</z:hpo> but infrequent in other types of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, with loss observed in 29% (29/101) of grade 1 or 2 and 39% (44/113) of grade 3 endometrioid <z:mp ids='MP_0002038'>carcinomas</z:mp> of the endometrium, 18% (17/95) of uterine serous <z:mp ids='MP_0002038'>carcinomas</z:mp> and 26% (6/23) of uterine clear cell <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Since <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancers</z:e> showed BAF250a loss, we stained whole tissue sections for BAF250a expression in nine cases of <z:mpath ids='MPATH_483'>atypical hyperplasia</z:mpath> and 10 cases of atypical <z:e sem="disease" ids="C0014175" disease_type="Disease or Syndrome" abbrv="">endometriosis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Of the nine cases of complex atypical <z:mp ids='MP_0009092'>endometrial hyperplasia</z:mp>, <z:hpo ids='HP_0000001'>all</z:hpo> showed BAF250a expression; however, of 10 cases of atypical <z:e sem="disease" ids="C0014175" disease_type="Disease or Syndrome" abbrv="">endometriosis</z:e> (the putative precursor lesion for ovarian clear cell and endometrioid <z:mp ids='MP_0002038'>carcinoma</z:mp>), one case showed loss of staining for BAF250a in the atypical areas, with retention of staining in areas of non-atypical <z:e sem="disease" ids="C0014175" disease_type="Disease or Syndrome" abbrv="">endometriosis</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>This was the sole case that recurred as an endometrioid <z:mp ids='MP_0002038'>carcinoma</z:mp>, indicating that BAF250a loss may be an early event in <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Since BAF250a loss is seen in <z:hpo ids='HP_0012114'>endometrial carcinomas</z:hpo> at a rate similar to that seen in <z:mp ids='MP_0003579'>ovarian carcinomas</z:mp> of clear cell and endometrioid type, and is uncommon in other <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, we conclude that loss of BAF250a is a particular feature of <z:mp ids='MP_0002038'>carcinomas</z:mp> arising from endometrial glandular epithelium </plain></SENT>
</text></document>